Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara (ASX:VHT) share price soars on 5-year contract

The ASX healthcare share Volpara Health Technologies Ltd (ASX: VHT) has revealed an exciting contract in the US.

The ASX healthcare share Volpara Health Technologies Ltd (ASX: VHT) has revealed an exciting contract. The Volpara share price has jumped 5%.

Volpara is a technology business that is primarily involved in helping identifying and protecting against cancer as early as possible.

Volpara’s great new contract

It revealed that it had signed a five-year contract with Banner Health, one of the largest non-profit hospital systems in the US. Banner Health operates 30 hospitals, including three academic medical centres.

This contract represents an additional US$1.25 million of total contract value (TACV).

The contract expansion includes upgrades and new installations of Volpara’s patient hub, analytics and risk pathways software across the Banner Health network.

Volpara said that the installation is expected to be completed within the next nine months. It includes annual payments is expected to “contribute to revenue growth in FY24”.

Management commentary

The Volpara CEO Teri Thomas said:

We are proud to expand our relationship with Banner Health and extend Volpara software to all their locations. This standardisation of care and implementation of new capabilities will help deliver more personalised care, find more cancers and identify high risk patients sooner so they can receive recommended interventions. We look forward to working with Banner Health to help save more families from cancer.

Thoughts on this for the Volpara share price

Clearly it’s a great step forward. To be recognised and chosen by such a large institution is very encouraging thing just by itself. But it could also be the start of being picked by more large US healthcare providers.

With such a strong gross profit margin, of over 90%, any revenue growth is highly helpful to the financials. This is a good boost to the company’s financial profile.

I think the business could be one of the best performing ASX shares over the rest of this decade, particularly if it’s able to make some progress with its lung cancer screening segment.

I believe it’s one of the most promising ASX growth shares to buy today.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content